Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation

Bone Marrow Transplant. 2021 Oct;56(10):2610-2612. doi: 10.1038/s41409-021-01407-6. Epub 2021 Jul 15.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • DNA (Cytosine-5-)-Methyltransferases / genetics*
  • DNA Methyltransferase 3A
  • DNA-Binding Proteins* / genetics
  • Dioxygenases
  • Humans
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / therapy
  • Middle Aged
  • Mutation
  • Neoplasm, Residual
  • Prognosis
  • Proto-Oncogene Proteins* / genetics
  • Repressor Proteins* / genetics
  • Stem Cell Transplantation

Substances

  • ASXL1 protein, human
  • DNA-Binding Proteins
  • DNMT3A protein, human
  • Proto-Oncogene Proteins
  • Repressor Proteins
  • Dioxygenases
  • TET2 protein, human
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A